首页> 美国卫生研究院文献>BMC Cancer >Application of Ventana immunocytochemical analysis on ThinPrep cytology slides for detection of ALK rearrangement in patients with advanced non–small-cell lung cancer
【2h】

Application of Ventana immunocytochemical analysis on ThinPrep cytology slides for detection of ALK rearrangement in patients with advanced non–small-cell lung cancer

机译:Ventana免疫细胞化学分析在ThinPrep细胞学载玻片上用于检测晚期非小细胞肺癌ALK重排的应用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundVentana ALK (D5F3) screening of anaplastic lymphoma kinase (ALK) gene rearrangement in tissue specimens has been approved by US FDA (Food and Drug Administration) to select treatment for non–small-cell lung carcinoma (NSCLC). However, tumor tissues are often not readily obtainable, and cytology specimens and may be the only tumor material available for diagnosis and molecular marker analysis. In this study, we evaluated the feasibility of ALK immunocytochemistry (ICC) on ThinPrep slides and determined a suitable scoring system for interpretation of the results.
机译:背景Ventana ALK(D5F3)对组织标本中的间变性淋巴瘤激酶(ALK)基因重排的筛选已获美国FDA(食品和药物管理局)批准,用于选择非小细胞肺癌(NSCLC)的治疗方法。然而,肿瘤组织通常不容易获得,并且细胞学标本可能是唯一可用于诊断和分子标记分析的肿瘤材料。在这项研究中,我们评估了ThinPrep载玻片上ALK免疫细胞化学(ICC)的可行性,并确定了合适的评分系统来解释结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号